Antibodies as cancer immunotherapy

Devalingam Mahalingam, Tyler J. Curiel*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of Chap. 12. Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy
Subtitle of host publicationParadigms, Practice and Promise
PublisherSpringer New York
Number of pages42
ISBN (Electronic)9781461447320
ISBN (Print)1461447313, 9781461447313
StatePublished - May 1 2013

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Antibodies as cancer immunotherapy'. Together they form a unique fingerprint.

Cite this